18
Jun
Glenmark Pharmaceuticals Limited (Glenmark) has launched the novel fixed-dose combination (FDC) drug - Indacaterol + Mometasone for patients suffering from uncontrolled asthma, in India. The company has launched this FDC under the brand name Indamet. The drug will be available in three strengths with a fixed dose of Indacaterol 150 mcg and variable doses of Mometasone 80 mcg, 160 mcg, and 320 mcg respectively. Asthma is a major non-communicable disease that affects more than 34 million people in India, causing thousands of deaths every year. Glenmark became the first company in India to market the innovative FDC of Indacaterol, a…